Navigation Links
Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
Date:11/9/2007

Oral Presentation by Dr. Robert Figlin Highlights Phase 2 Data Showing 31% Partial Response Rate and a 62% Overall Clinical Benefit Rate to Perifosine Used as a Single Agent and Phase 1 Data Showing No Evidence of Increased

Toxicity When Combined with Sorafenib

NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced positive phase 1 & 2 data of perifosine (KRX-0401) in patients with advanced renal cell carcinoma (RCC). In an oral presentation entitled "PERIFOSINE: AN ORAL, AKT INHIBITOR WITH CLINICAL ACTIVITY IN ADVANCED RENAL CELL CARCINOMA," Dr. Robert Figlin, Medical Oncology Chair and Professor of Medicine, City of Hope National Medical Center in Duarte, CA provided an update on the clinical activity of single agent perifosine from a phase 2 trial (Protocol 207), and reported on the safety and efficacy of perifosine in combination with sorafenib from an ongoing phase I study (Protocol 124).

Phase 2 Single Agent in RCC - Protocol 207

Twenty-four patients with advanced renal cell carcinoma (RCC) were randomized to either the daily (50 mg or 100mg) or weekly (900mg or 1200mg) dose of perifosine. Patients with measurable disease who received at least 2 courses of perifosine and at least one tumor measurement after initiation of perifosine, were considered evaluable for response using RECIST criteria. Thirteen were evaluable for response. Four of these (31%) had a partial response and an additional 4 patients (31%) achieved long-term stable disease for a 62% overall clinical benefit rate. Five patients progressed. One of the responding patients had previously failed to respond to both sorafenib and sunitinib. The results are as follows:

50 1200

or or

100 mg 900 mg

Protocol 207
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; or ... Small Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) ... Diseases (NIAID), a division of the National Institutes ... human antibody therapeutics to combat Staphylococcus aureus ... including methicillin-resistant S. aureus (MRSA), was ...
(Date:5/17/2013)... 17, 2013  Sony Biotechnology Inc. ("Sony") today announced the ... and 130um sorting chip.  Sony will also be exhibiting its ... SH800 Cell Sorter, the EC800 flow cytometer, and new SP6800 ... 2013, which will be held at the San ... California , from May 20 - 22.  ...
(Date:5/17/2013)... , May 17, 2013  TechAtlas Group ... for their competitive landscape map for the Chronic ... over 90 international companies with drugs and devices ... CKD and its sequelae. (Logo:  ... , hypertension - renal denervation ...
Breaking Medicine Technology:Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Sony Delivers New Technology for Science to CYTO 2013 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2
... Call to discuss the company,s third quarter financial ... 11:00 a.m. EDT (8:00 a.m. PDT). SUNNYVALE, Calif., ... PCYC ) today announced that it has entered ... leading French independent pharmaceutical company. The alliance will ...
... TLR8 Agonist to Advance for Treatment of AllergySAN DIEGO ... biopharmaceutical company focused on the development of novel Toll-Like ... respiratory and inflammatory diseases, announced today that it has ... selective intranasal TLR8 agonist for the treatment of allergic ...
Cached Medicine Technology:Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier 2Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier 3Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier 4Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier 5VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis 2
(Date:5/17/2013)... 2013 Degenerative changes to the area of ... with compression, known as the nucleus pulposus, has been demonstrated ... new study led by researchers at the Icahn School of ... journal PLOS ONE, reinforces the importance of diabetes in inducing ... is the first study to demonstrate that these changes can ...
(Date:5/17/2013)... A May 13, 2013 report by CNN ... Getting Surgery” examines the typical motivation of post-divorce ... to the article these patients typically fit into three ... freshen their look because they’re now back on the ... plastic surgery before their divorce but never went ...
(Date:5/17/2013)... New York (PRWEB) May 17, 2013 ... dedicated to protecting the rights of victims injured by ... DePuy Orthopaedics Inc. has said in a May 16, ... some of its metal-on-metal and ceramic-on-metal hip replacement products; ... and the Complete Ceramic-on-Metal Acetabular Hip System will no ...
(Date:5/17/2013)... women in Texas who are found to have an ... one of their breasts end up having an old-fashioned ... is malignant. Since 2001, national expert panels have recommended ... breast lumps or masses should be minimally invasive biopsy. ... ultrasonographic or X-ray guidance, with either a fine needle ...
(Date:5/17/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- There ... a musical instrument and a GPS system, and now there,s ... you,re having a heart attack. The app, which was ... diagnose certain kinds of severe heart attacks, called STEMIs, before ... in the experimental stage, but it has undergone field testing. ...
Breaking Medicine News(10 mins):Health News:Degenerative Changes Identified in Spinal Discs and Reversed With Drug Cocktail In Diabetic Mice 2Health News:Degenerative Changes Identified in Spinal Discs and Reversed With Drug Cocktail In Diabetic Mice 3Health News:Degenerative Changes Identified in Spinal Discs and Reversed With Drug Cocktail In Diabetic Mice 4Health News:Plastic Surgery – Is ‘Revenge’ Cosmetic Surgery on the Rise? 2Health News:Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products 2Health News:Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products 3Health News:More than one-third of Texas women still receive unnecessary breast biopsy surgery 2Health News:Heart Attack? Doctors Soon May Have an App for That 2Health News:Heart Attack? Doctors Soon May Have an App for That 3
... about half of women age 65 and older would be ... rate for women falls to 12 percent. These facts ... in the latest installment of the Public Policy & Aging ... Society, the public policy branch of The Gerontological Society of ...
... Reporter , THURSDAY, Dec. 16 (HealthDay News) -- Federal ... drug Avastin to fight breast cancer, citing the medication,s ... serious side effects. But the recommendation, announced by ... news conference, will not immediately affect breast cancer patients, ...
... The American Heart Association has recognized UC Irvine Healthcare,s ... patients. The Get With The Guidelines Heart Failure ... achieved at least 85 percent compliance for one year with ... medical center,s compliance rate was 96 percent. The "Plus" designation ...
... December 16, 2010 The Elsevier Foundation has ... Innovative Libraries in Developing Countries program, committing over ... developing countries. The 2010 grant recipients were selected ... potential for impact in the developing world. The ...
... World Health Organization set a target for the influenza vaccination ... population and an increase to more than 75% by 2010. ... old German states. In the current issue of Deutsches ... 845󈞞) the working group around Annicka M. Reuss presents rates ...
... Reporter , THURSDAY, Dec. 16 (HealthDay News) -- Researchers ... -- the part of the brain believed to generate ... improve treatment for post-traumatic stress disorder (PTSD) and other ... confirming that the almond-shaped structure is crucial for triggering ...
Cached Medicine News:Health News:Brief clarifies Social Security's value for women 2Health News:FDA Advises Against Avastin as Treatment for Breast Cancer 2Health News:FDA Advises Against Avastin as Treatment for Breast Cancer 3Health News:UC Irvine Medical Center recognized for heart failure program 2Health News:Elsevier Foundation announces 2010 grants for libraries in developing countries 2Health News:Brain Anomaly Leaves Woman Without Fear 2Health News:Brain Anomaly Leaves Woman Without Fear 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: